Orthofix Investor Presentation Deck
IN
Meaningful Revenue
& Cost Synergies
✓
Est. Revenue Synergies: >$25M
Est. Cost Synergies:~$40M*
Revenue Risk to Manage:
~$20M**
Working Capital & Capex
Synergies
Merger Highlights
88
Complementary
Portfolios
#1 Prescribed bone
growth stimulator
portfolio in the U.S.
Broadest advanced DBM
portfolio, market leading cellular
allograft, and shelf- stable
allograft on the market
Next generation differentiated
artificial cervical disc
'Cost synergies of $40M expected by 2025 with incremental opportunity to reduce stock-based compensation expense
"Based on due diligence, including revenue zip code analysis performed by 3rd party
©2023 Orthofix Medical Inc. All rights reserved | 16
Å
Broader
Commercial Reach
✓ Accelerated adoption of
differentiated technologies
Sustainable growth & value
creation
Strengthened U.S. and
international sales channels
Rapid product innovation
driving market-share taking
ORTHOFIX®
SeaSpine.View entire presentation